Ipratropium Bromide and Salbutamol
Product Description
QILU PHARMACEUTICAL CO., LTD.
-
Country/Region:China
-
On CPHI since:2015
-
Employees:5000+
Company types
Categories
Specifications
QILU PHARMACEUTICAL CO., LTD.
-
Country/Region:China
-
On CPHI since:2015
-
Employees:5000+
Company types
More Products from QILU PHARMACEUTICAL CO., LTD. (26)
-
Product Aprepitant
Aprepitant, a highly selective neurokinin-1 receptor antagonist, provides superior protection against both acute and delayed chemotherapy-induced nausea and vomiting compared to conventional antiemetic agents, with a single dose offering sustained efficacy over many hours. Its ability to be combined with 5... -
Product atezolizumab
Atezolizumab is an anti-PD-L1 mAb and the first approved for NSCLC first-line immunotherapy combinations. With differentiated positioning in urothelial carcinoma and HCC (combined with bevacizumab), it remains a significant competitor in the PD-L1 landscape. -
Product bevacizumab
Bevacizumab is a humanized anti-VEGF-A mAb inhibiting tumor angiogenesis across multiple solid tumors. As the cornerstone anti-angiogenic agent with broad combination potential, it commands massive market volume with an established biosimilar competitive landscape. -
Product Bupivacaine
Bupivacaine utilizes proprietary DepoFoam technology to encapsulate bupivacaine within multivesicular liposomes, enabling sustained analgesia for up to 72 hours through a unique tri-phasic release mechanism involving initial burst, membrane diffusion, and particle erosion. This prolonged duration of action... -
Product daratumumab
Daratumumab is an anti-CD38 mAb for multiple myeloma across all lines of therapy. From first-line to relapsed settings, its subcutaneous Faspro formulation compresses infusion from hours to minutes, making it the absolute cornerstone of MM treatment. -
Product denosumab
Denosumab is a human anti-RANKL mAb; Prolia for osteoporosis and Xgeva for bone metastases. Its semiannual subcutaneous dosing offers superior compliance vs oral bisphosphonates, with dual-market positioning across orthopedics and oncology. -
Product Leuprorelin (3M, 6M)
Leuprorelin uses lyophilized microsphere technology with leuprolide acetate embedded in biodegradable PLGA polymer microcapsules. The active drug is released in two phases—diffusion and bioerosion—enabling 3-month or 6-month dosing intervals. As a GnRH agonist, it induces pituitary desensitization to reduc... -
Product Nusinersen
Nusinersen is a modified antisense oligonucleotide (ASO) administered intrathecally. It binds to the ISS-N1 sequence in intron 7 of SMN2 pre-mRNA, promoting exon 7 inclusion and production of full-length functional SMN protein. Approved across all SMA phenotypes including Type I, II, III, and presymptomati... -
Product ocrelizumab
Ocrelizumab is an anti-CD20 mAb and the only approved disease-modifying therapy for primary progressive multiple sclerosis (PPMS). With semiannual infusion and nearly 50% reduction in annualized relapse rate for RMS, it holds an unmatched position in neuroimmunology. -
Product Octreotide Acetate
Octreotide Scetate is a long-acting release formulation of octreotide acetate encapsulated in biodegradable PLGA microspheres, providing sustained release for approximately 28 days following intramuscular injection. It dramatically improves patient adherence and quality of life compared to multiple daily s... -
Product ofatumumab
Ofatumumab is an anti-CD20 mAb; Arzerra for CLL and Kesimpta for relapsing multiple sclerosis. Its monthly subcutaneous self-injection enables thorough B-cell depletion with significantly superior compliance vs intravenous CD20 alternatives. -
Product Paclitaxel
Paclitaxel is a Cremophor-free, albumin-bound paclitaxel formulation where paclitaxel is delivered in a suspension of albumin nanoparticles. It is administered as a 30-minute IV infusion without steroid or antihistamine premedication. It eliminates the need for Cremophor EL solvent, thereby removing the ri...